Clinical Trial Update: Intravenous Ferric Carboxymaltose (Ferinject®) With or Without Erythropoietin in Patients Undergoing Orthopaedic Surgery [Phase 4]

View source ↗

Summary

Phase 4 trial update indicates termination of a study evaluating intravenous ferric carboxymaltose (Ferinject) with or without erythropoietin in iron deficiency…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iron Deficiency Anemia

Drugs mentioned

• Erythropoietin (erythropoietin)
• Ferinject (ferric carboxymaltose)

Snippet

Sponsor: University of Zurich | Conditions: Iron Deficiency Anemia | Phase 4 | Status: TERMINATED